within Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AX03_Sultiame;

model Sultiame
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.85,
    Cl = 1.5555555555555556e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.0005,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0033333333333333335,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Sultiame</td></tr><tr><td>ATC code:</td><td>N03AX03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.08</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Sultiame is a carbonic anhydrase inhibitor used as an anticonvulsant, primarily for the treatment of epilepsy, particularly in children with benign childhood epilepsy with centrotemporal spikes (BECTS). It is not approved in all countries and its use is mainly in Europe and Australia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for adults based on sparse data and secondary literature sources as primary literature with detailed compartmental PK modeling is lacking.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N03AX03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Sultiame;
